ARIA News 5.37 07/17/2014 04:36:49 Ariad Pharmaceuticals (AR

New Post Public Reply Private Reply Replies (0) Message Board

Jul 17, 2014 at 5:36 AM

Ariad Pharmaceuticals (ARIA) 5.37 $ARIA

Yellen, Icahn Comments Put a Lid on Small-Cap Stocks, May Hurt Larger Market
at The Street - Wed Jul 16, 10:40AM CDT
Recent comments by Fed Chair Janet Yellen and activist investor Carl Icahn have led to selling pressure in small-cap stocks.

ARIAD to Webcast Conference Call on Second Quarter 2014 Financial Results
Business Wire - Wed Jul 16, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2014 financial results on Wednesday, August 6, 2014, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update.

Ariad Stock's Biggest Risk Is Its Only Hope
Brian Wilson, The Motley Fool - Motley Fool - Tue Jul 15, 4:00PM CDT
Overreliance on its blood cancer drug Iclusig (ponatinib) continues to make Ariad Pharmaceuticals an incredibly risky biotech play, despite the mature company's relatively low market cap of $1.1 billion. After a dramatic FDA recall in 2013 based...

Stock Market Today: Social Media, Biotech Suffer as Janet Yellen Shares Concerns on Valuation
at The Street - Tue Jul 15, 3:19PM CDT
Major indices trembled and the Nasdaq slid Tuesday following Fed Chair Janet Yellen's remarks on biotech and social media valuations.

ARIAD Announces Continuation of Iclusig Review under the Article 20 Procedure in Europe
Business Wire - Mon Jul 14, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has provided the Company with a request for limited additional information regarding Iclusig(R) (ponatinib) as part of its ongoing review under the Article 20 referral procedure. The PRAC has requested further information regarding proposed dose modifications after achievement of a response and patient monitoring and details concerning a risk management plan. Following ARIAD's response and input from the agency's Scientific Advisory Group, the Company expects that the PRAC will complete its review and make final recommendations to the Committee for Medicinal Products for Human Use (CHMP) at its meeting in October 2014.

ARIAD Pharmaceuticals (ARIA) Is Water-Logged And Getting Wetter Today
at The Street - Tue Jul 08, 9:39AM CDT
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

UCB, Dermira Sign Cimzia Dermatology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 5:10PM CDT
UCB SA (UCBJF) and Dermira have entered into a licensing agreement for the development and commercialization of Cimzia in dermatology.

OncoGenex's Apatorsen in Phase II for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 3:30PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that apatorsen is in phase II study (Cedar) for advanced squamous cell lung cancer.

Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 7:42AM CDT
Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock

Alcobra (ADHD) Jumps: Stock Adds 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 8:46AM CDT
Alcobra (ADHD) was a big mover last session, with shares rising nearly 6% on the day.

Zogenix, Inc. (ZGNX) Soars: Stock Adds 18.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 03, 7:51AM CDT
Zogenix, Inc. (ZGNX) was a big mover last session, as its shares rose nearly 19% on the day.

Amgen Gets Breakthrough Therapy Status for Leukemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 4:55PM CDT
Amgen (AMGN) announced that the FDA has granted Breakthrough Therapy Designation to its experimental oncology drug, blinatumomab.

Ariad Pharmaceuticals Up 75.1% Since SmarTrend Uptrend Call (ARIA)
Comtex SmarTrend(R) - Wed Jul 02, 9:35AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on November 22nd, 2013 at $3.67. In approximately 7 months, Ariad Pharmaceuticals has returned 75.07% as of today's recent price of $6.43.

Tesaro (TSRO) in Focus: Stock Moves 8.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 8:46AM CDT
Tesaro (TSRO) was a big mover last session, with shares rising nearly 9% on the day.

Karyopharm Therapeutics (KPTI) in Focus: Stock Goes Down 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 7:59AM CDT
Karyopharm Therapeutics stock fell 5.2% last trading session, reversing its recent trend

Salix Pharmaceuticals (SLXP) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 02, 7:51AM CDT
Salix Pharmaceuticals Ltd. (SLXP) was a big mover last session, as its shares rose over 11% on the day.

IGI Laboratories (IG) Worth Watching: Stock Rises 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:25AM CDT
IGI Laboratories (IG) was a big mover last session, with shares rising over 6% on the day.

Auxilium Pharmaceuticals (AUXL) Crumbles: Stock Falls by 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 7:59AM CDT
Auxilium Pharmaceuticals has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month

UCB's Vimpat Positive for Partial-Onset Seizures - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 10:50AM CDT
UCB SA (UCBJF) announced positive data from two studies on Vimpat as an early adjunctive therapy in adults suffering from partial-onset seizures.

Pacira's Exparel Positive in Phase IV Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 10:30AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) announced significant results from a series of phase IV studies on Exparel.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CELSET Unveils SOLTOX: Expanding in Global Markets

New Contender in the Global Botulinum Toxin Arena Launching a fresh player onto the international stage, CELSET INC. from Seoul throws down with SOLTOX, their own botulinum toxin Type A brand. This ain't your run-of-the-mill roll-out; it's another notch for Korean biotech trying to snag a piece of global market action. A Look at SOLTOX's Technical Makeup We’re talking...

Banco Macro S.A. Plans $160B Share Buyback Initiative

Tapping into Share Buybacks in a Tumultuous Market Out of nowhere, Banco Macro S.A. has decided to whip up a share buyback program, a lifeline for their current market value. Let me tell you, the market's more volatile than a caffeinated squirrel these days, hitting the financial scenery harder than a hammer on a glass table. So, Banco Macro's taken a deep breath and...

Enertech's New Moves Aim to Make Geothermal Mainstream

Breaking Through Financial Barriers in Geothermal Energy Finally, we're seeing some real movement in the geothermal heat pump sector. The longtime hurdles that kept ground-sourced heating and cooling tech at arm's length from the everyday homeowner are starting to tumble, thanks to Enertech Global's latest initiatives. Enertech's Double Deal: A New Lease on Geothermal...

Agrochemicals: Combining Tradition and Innovation

The Evolving World of Agrochemicals You know, the agrochemical market isn't just about fertilizers and pesticides anymore. It's evolving into a high-stakes game of innovation, resistance management, and cutting-edge tech. This whole sector's forecast to explode to a whopping US$ 387.7 billion by 2031. That's no small potatoes. Driving Forces: Pests, Drones, and Regulatory...

Insurify's AI Gateway: A New Era in Insurance Shopping

Insurify's Game-Changing AI Agent Gateway In the insurance world, Insurify's latest move feels like a bull charging through a ticker tape parade. This Cambridge-based pioneer unveiled its AI Agent Gateway, aiming to put consumers back in the driver's seat. By connecting digital assistant agents to its platform, Insurify's making insurance shopping a bit less like pulling...

Royce Micro-Cap Trust: Navigating Small-Cap Waves

Folks, if there's ever been a niche in this labyrinth of stocks, it’s the micro-cap territory. Royce Micro-Cap Trust (NYSE: RMT) is hefting the torch for smaller companies up to a billion in market cap. But is it leading the charge or getting steamrolled by market bear crawls? Understanding the Numbers Time to get dirty with some numbers, because for Royce Micro-Cap...

Pave and Levels.fyi Unite: Revolutionize Pay Decisions

Diving straight into the heart of it, here's a move in the business world that's all but marking its territory on the compensation landscape. Pave, already a big player in agentic compensation management, is shaking hands with Levels.fyi, a platform prized for its real-deal compensation data detailed down to the company, level, location, and skill. These folks are...

Innovative Trial Targets Drug Resistance in Lung Cancer

The Battle Against Drug Resistance Heats Up Folks, we're in a never-ending fight here against one of the toughest adversaries out there: lung cancer. And lemme tell ya, when drugs show resistance, it's like trying to punch a ghost. But there’s a fresh wind blowing, as Dr. Bobak Parang steps up to the plate with a $620K grant aimed squarely at tackling drug resistance in...

Photocure's Q3 2026: Revenue Plateau and CFO Shakeup

The Bladder Cancer Scene: Steady as She Goes Sometimes, you look at numbers and find tranquility, like staring into still waters. That's the scene over at Photocure ASA with their latest Q3 results. Clocking in with revenues of NOK 134.2 million from their Hexvix®/Cysview® products, they're barely flinching from last year's NOK 134.1 million. Is it a victory or a...

Royce Small-Cap Trust Shows Resilience Amid Volatility

A Closer Look at Royce's Latest Moves Royce Small-Cap Trust (NYSE: RVT), the venerable old timer in the small-cap fund world, has been trucking along the market's bumpy byways since forever ago. With over 50 years of small- and micro-cap investment experience under its belt, you'd think it might have seen everything by now. But in the volatile world of small caps,...